Order Article Reprints

Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, et al. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2023; 15(5):1568. https://doi.org/10.3390/cancers15051568

Tokunaga, Takayuki, Masakuni Tateyama, Yasuteru Kondo, Satoshi Miuma, Shiho Miyase, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Yoko Yoshimaru, and et al. 2023. "Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma" Cancers 15, no. 5: 1568. https://doi.org/10.3390/cancers15051568

Tokunaga, T., Tateyama, M., Kondo, Y., Miuma, S., Miyase, S., Tanaka, K., Narahara, S., Inada, H., Kurano, S., Yoshimaru, Y., Nagaoka, K., Watanabe, T., Setoyama, H., Fukubayashi, K., Tanaka, M., & Tanaka, Y. (2023). Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers, 15(5), 1568. https://doi.org/10.3390/cancers15051568